Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00126412 · ClinicalTrials.gov registry record · Phase 3
Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
A Phase 3 study, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 251
- Enrollment target
NCT00126412: Completed Phase 3 study, sponsored by GE Healthcare.
NCT00126412 is a Phase 3 study that has completed, run by GE Healthcare. The registered enrollment target is 251 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00126412, a Phase 3 study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 251 participants
- Enrollment target
Study Summary
The study is designed to study the effectiveness of 123I-mIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroblastoma or phaeochromocytoma.
Interventions
- DRUG 123I-mIBG (meta-iodobenzylguanidine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2005-08-02 |
| Est. Completion | 2006-09-27 |
| Phase | Phase 3 |
What the finished NCT00126412 record still lists
NCT00126412 is an interventional study that assigns participants to a tested intervention. The registered 251 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 1 intervention - of which 123I-mIBG (meta-iodobenzylguanidine) is the first listed.
NCT00126412 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00126412 about?
NCT00126412 is a clinical study titled "Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma". The study is designed to study the effectiveness of 123I-mIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroblastoma or phaeochromocytoma.
What is the current status of trial NCT00126412?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 251 participants. The study started on 2005-08-02. Estimated completion is 2006-09-27.
What interventions are being tested in trial NCT00126412?
The interventions under investigation include: 123I-mIBG (meta-iodobenzylguanidine) (DRUG).
Who is sponsoring clinical trial NCT00126412?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00126412's enrollment target sits among peer trials
251 1249th of 2000 higher than 752 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06043817 · 251 participants · Phase 1
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI